Skin rash composition after checkpoint inhibitor therapy varies by therapeutic regimen

Name: Skin rash composition after checkpoint inhibitor therapy varies by therapeutic regimen
Creator: Cory Kosche
Published: 2022-05-05T12:28:26.733Z
Keywords: Immunotherapy, T Cell, Skin Rash, Immune Checkpoint Inhibitor

Kosche, Cory; Jaishankar, Dinesh; Cosgrove, Cormac; Ramesh, Prathyaya; Hong, Suyeon; Li, Lin; Shivde, Rohan; Bhuva, Deven; Perez White, Bethany; Munir, Sabah; Zhang, Hui; Choi, Jennifer; Le Poole, I. Caroline

doi:10.17632/hw4j2k8xt3.1

Skin rash composition after checkpoint inhibitor therapy varies by therapeutic regimen

Published: 5 May 2022| Version 1 | DOI: 10.17632/hw4j2k8xt3.1

Contributors:

Cory Kosche, Dinesh Jaishankar, Cormac Cosgrove, Prathyaya Ramesh, Suyeon Hong, Lin Li, Rohan Shivde, Deven Bhuva, Bethany Perez White, Sabah Munir, Hui Zhang, Jennifer Choi, I. Caroline Le Poole

Description

Patient skin rash and control cell counts.

Files

Steps to reproduce

Obtain human patient control and rash skin. Section and fix tissues appropriately. Conduct immunoenzymatic or immunofluorescent stainings, calculate area, and use microscopy to evaluate and quantify.

Institutions

Northwestern University - Chicago

Skin rash composition after checkpoint inhibitor therapy varies by therapeutic regimen

Description

Files

Steps to reproduce

Institutions

Categories

Licence